Table 2.
Patient Baseline Characteristics, Stratified by Index Medication (N=64 661)
| Apixaban (n=3900, 6.0%) | Dabigatran (n=10 235, 15.8%) | Rivaroxaban (n=12 336, 19.1%) | Warfarin (n=38 190, 59.1%) | Total (n=64 661) | |
|---|---|---|---|---|---|
| Age, y, median (IQR) | 72 (64–80) | 69 (60–77) | 70 (62–78) | 75 (67–81) | 73 (64–80) |
| Age, n (%) | |||||
| 18–54 y | 331 (8.5) | 1356 (13.2) | 1284 (10.4) | 2136 (5.6) | 5107 (7.9) |
| 55–64 y | 737 (18.9) | 2565 (25.1) | 2667 (21.6) | 5144 (13.5) | 11 113 (17.2) |
| 65–74 y | 1207 (30.9) | 3091 (30.2) | 3955 (32.1) | 11 707 (30.7) | 19 960 (30.9) |
| ≥75 y | 1625 (41.7) | 3223 (31.5) | 4430 (35.9) | 19 203 (50.3) | 28 481 (44.0) |
| Male, n (%) | 2137 (54.8) | 6337 (61.9) | 7250 (58.8) | 20 586 (53.9) | 36 310 (56.2) |
| Race, n (%) | |||||
| Asian | 89 (2.3) | 259 (2.5) | 304 (2.5) | 776 (2.0) | 1428 (2.2) |
| Black | 351 (9.0) | 854 (8.3) | 1054 (8.5) | 3657 (9.6) | 5916 (9.1) |
| Hispanic | 193 (4.9) | 450 (4.4) | 597 (4.8) | 1827 (4.8) | 3067 (4.7) |
| Unknown | 185 (4.7) | 485 (4.7) | 591 (4.8) | 1831 (4.8) | 3092 (4.8) |
| White | 3082 (79.0) | 8187 (80.0) | 9790 (79.4) | 30 099 (78.8) | 51 158 (79.1) |
| Region, n (%) | |||||
| Midwest | 1083 (27.8) | 2625 (25.6) | 3311 (26.8) | 13 784 (36.1) | 20 803 (32.2) |
| Northeast | 710 (18.2) | 2025 (19.8) | 2324 (18.8) | 7257 (19.0) | 12 316 (19.0) |
| South | 1648 (42.3) | 4491 (43.9) | 5401 (43.8) | 13 036 (34.1) | 24 576 (38.0) |
| West | 459 (11.8) | 1094 (10.7) | 1300 (10.5) | 4113 (10.8) | 6966 (10.8) |
| Comorbidities, n (%) | |||||
| Congestive heart failure | 1110 (28.5) | 2460 (24.0) | 3162 (25.6) | 14 866 (38.9) | 21 598 (33.4) |
| Hypertension | 3321 (85.2) | 8410 (82.2) | 10 219 (82.8) | 33 100 (86.7) | 55 050 (85.1) |
| Diabetes | 1321 (33.9) | 3233 (31.6) | 3907 (31.7) | 14 677 (38.4) | 23 138 (35.8) |
| Ischemic stroke/transient ischemic attack | 501 (12.8) | 1185 (11.6) | 1351 (11.0) | 6250 (16.4) | 9287 (14.4) |
| Vascular disease | 1907 (48.9) | 4488 (43.8) | 5527 (44.8) | 21 067 (55.2) | 32 989 (51.0) |
| Renal disease | 678 (17.4) | 1201 (11.7) | 1764 (14.3) | 10 105 (26.5) | 13 748 (21.3) |
| Liver disease | 139 (3.6) | 335 (3.3) | 452 (3.7) | 1635 (4.3) | 2561 (4.0) |
| Major bleeding or predisposition to bleeding | 459 (11.8) | 1096 (10.7) | 1400 (11.3) | 7013 (18.4) | 9968 (15.4) |
| CHA2DS2‐VASc score, n (%) | |||||
| 0 or 1 | 423 (10.8) | 1847 (18.0) | 1848 (15.0) | 2580 (6.8) | 6698 (10.4) |
| 2 or 3 | 1242 (31.8) | 3608 (35.3) | 4302 (34.9) | 9809 (25.7) | 18 961 (29.3) |
| 4 | 872 (22.4) | 2014 (19.7) | 2545 (20.6) | 8323 (21.8) | 13 754 (21.3) |
| ≥5 | 1363 (34.9) | 2766 (27.0) | 3641 (29.5) | 17 478 (45.8) | 25 248 (39.0) |
| HAS‐BLED, n (%) | |||||
| ≥3 | 1707 (43.8) | 3842 (37.5) | 4933 (40.0) | 20 439 (53.5) | 30 921 (47.8) |
| Charlson–Deyo index, n (%) | |||||
| 0–1 | 1646 (42.2) | 5021 (49.1) | 5722 (46.4) | 11 814 (30.9) | 24 203 (37.4) |
| 2–3 | 1245 (31.9) | 3010 (29.4) | 3681 (29.8) | 11 457 (30.0) | 19 393 (30.0) |
| ≥4 | 1009 (25.9) | 2204 (21.5) | 2933 (23.8) | 14 919 (39.1) | 21 065 (32.6) |
CHA 2 DS 2‐VASc, risk based on the presence of congestive heart failure, hypertension, age 65–74 y, age ≥75 y, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, sex category; HAS‐BLED, risk stratification scheme to estimate baseline risk of major hemorrhage based on the presence of hypertension, abnormal renal function, abnormal liver function, stroke, bleeding history or predisposition, age > 65 y, antiplatelet or nonsteroidal anti‐inflammatory drug use and alcoholism.